| Previous Close | 3.88 |
| Open | 3.86 |
| Volume | 86,572 |
| Avg. Volume (3M) | 509,384 |
| Market Cap | 1,180,968,320 |
| Price / Earnings (TTM) | 16.48 |
| Price / Earnings (Forward) | 7.91 |
| Price / Sales | 1.82 |
| 52 Weeks Range | |
| Earnings Date | 18 Mar 2026 |
| Profit Margin | 16.42% |
| Operating Margin (TTM) | 7.97% |
| Diluted EPS (TTM) | 0.370 |
| Quarterly Revenue Growth (YOY) | 260.00% |
| Quarterly Earnings Growth (YOY) | -65.50% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -148.89 M |
| Levered Free Cash Flow (TTM) | -216.76 M |
| Return on Assets (TTM) | 7.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Alvotech | Mixed | Bearish |
AIStockmoo Score
-1.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Average | -1.17 |
|
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 63.44% |
| % Held by Institutions | 6.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lodbrok Capital Llp | 30 Sep 2025 | 181,587 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® |
| 05 Feb 2026 | Announcement | Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® |
| 02 Feb 2026 | Announcement | Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates |
| 02 Feb 2026 | Announcement | Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates |
| 29 Jan 2026 | Announcement | Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg |
| 29 Jan 2026 | Announcement | Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |